A new blood test that can detect the presence of Alzheimer’s brain plaques became the first to hit the commercial market on a wide scale in late October, according to developer C2N Diagnostics.
The PrecivityAD test can detect the presence of biomarkers for amyloid beta, a hallmark of the disease, and is consistent with the results of a diagnostic brain scan.
“While the test by itself cannot diagnose Alzheimer’s disease … the test is an important new tool for physicians to aid in the evaluation process,” C2N Diagnostics said.
It is available in 45 states, Washington, D.C., and Puerto Rico.
From the December 2020 Issue of McKnight's Long-Term Care News
